Andrew Hirsch - 13 Feb 2026 Form 4 Insider Report for C4 Therapeutics, Inc. (CCCC)

Reporting relationship: President & CEO, Director
Issuer ticker: CCCC
Reported as of: 13 Feb 2026
Net transaction value: -$91,119
SEC form: 4
Accepted by SEC: 18 Feb 2026, 17:04:58 UTC
Prior SEC filing: 10 Jun 2025
Next SEC filing: 22 Jun 2026
Source filing: View source filing
Reporting owner signature: /s/ Shagha Russell, Attorney-in-Fact

Key filing fact

Andrew Hirsch filed Form 4 for C4 Therapeutics, Inc. (CCCC) on 18 Feb 2026.

Key facts

This page summarizes Andrew Hirsch's Form 4 filing for C4 Therapeutics, Inc. (CCCC).
5 reported transactions and 0 derivative rows are listed below.
Accepted by SEC: 18 Feb 2026, 17:04.

Change

Previous filing in this sequence was filed on 10 Jun 2025.
Current net transaction value: -$91,119.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001586707 Primary reporting owner

Hirsch Andrew

Relationship: President & CEO, Director
Address: C/O C4 THERAPEUTICS, INC., 490 ARSENAL WAY #120, WATERTOWN
Signature: /s/ Shagha Russell, Attorney-in-Fact
Signature date: 18 Feb 2026

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

CCCC transaction

Common Stock

Award

Transaction value: $0
Shares: +700,000
Change %: +165%
Price: $0.000000
Shares after: 1,123,145
Date: 13 Feb 2026
Ownership: Direct
Footnotes: F1

CCCC transaction

Common Stock

Options Exercise

Transaction value: $0
Shares: +81,725
Change %: +7.8%
Price: $0.000000
Shares after: 1,123,145
Date: 14 Feb 2026
Ownership: Direct
Footnotes: F2

CCCC transaction

Common Stock

Tax liability

Transaction value: $74,001
Shares: -39,154
Change %: -3.5%
Price: $1.89
Shares after: 1,083,991
Date: 14 Feb 2026
Ownership: Direct
Footnotes: F3

CCCC transaction

Common Stock

Options Exercise

Transaction value: $0
Shares: +20,400
Change %: +1.9%
Price: $0.000000
Shares after: 1,083,991
Date: 15 Feb 2026
Ownership: Direct
Footnotes: F2

CCCC transaction

Common Stock

Tax liability

Transaction value: $17,118
Shares: -9,057
Change %: -0.84%
Price: $1.89
Shares after: 1,074,934
Date: 15 Feb 2026
Ownership: Direct
Footnotes: F3

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 3 footnotes

Footnote F1

Represents restricted stock units ("RSUs"). Each RSU represents the contingent right to receive one share of the Issuer's Common Stock upon vesting and settlement. The RSUs shall vest as follows: (i) 350,000 RSUs shall vest in three equal annual installments following the grant date, with the first installment vesting on February 13, 2027, and (ii) 350,000 RSUs shall vest in full on February 13, 2029, subject to potential acceleration upon achievement of certain performance milestones.

Footnote F2

Reflects the acquisition of shares of Common Stock upon vesting of previously disclosed grants of RSUs. The grants of RSUs were initially reported in Table I of the Forms 4 filed by the Reporting Person on February 15, 2023, February 15, 2024 and February 18, 2025.

Footnote F3

Represents shares withheld by the Issuer to satisfy tax withholding obligations in connection with the vesting and settlement of RSUs and does not represent a sale by the Reporting Person.

SEC remarks

Exhibit 24 - Power of Attorney